Gene · 8205
TAM: Myeloproliferative syndrome, transient (transient abnormal
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. TAM: Myeloproliferative syndrome, transient (transient abnormal. Genes, record 8205. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8205
On this page
Gene
- Symbol
- TAM
- Name
- Myeloproliferative syndrome, transient (transient abnormal
- NCBI Gene ID
- 8205
- Aliases
- MST
- Type
- unknown
Source NCBI Gene
Proteins0
Reviewed human proteins whose Swiss-Prot entry states the gene.
None in this release.
Patents0
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
None in this release.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,201
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TAM papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 15 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 7 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 4 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 4 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 4 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 3 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,201Source NIH's project files
See all 1,201 nih grantsPapers2,064
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Structural organization of TAM receptor ectodomains. | Biochem J | 2026 | 42770830 | PubTator, text mining | PubMed |
| Macrophage-directed therapeutic strategies in cancer. | Trends Cancer | 2026 | 42767905 | PubTator, text mining | PubMed |
| Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages. | Sci Adv | 2026 | 42758830 | PubTator, text mining | PubMed |
| Siglec-15 Expression in Gastric Carcinoma and Its Association With Clinicopathological Variables. | World J Oncol | 2026 | 42730210 | PubTator, text mining | PubMed |
| B3GNT5-associated glycosylation remodeling in tumor-associated macrophages supports TGF-β-related glioma progression. | Biochim Biophys Acta Gen Subj | 2026 | 42715804 | PubTator, text mining | PubMed |
| TAMing the tumor: targeting immune inhibitory receptors on tumor-associated macrophages in pediatric brain tumors - an emerging immunotherapy strategy. | J Immunother Cancer | 2026 | 42705864 | PubTator, text mining | PubMed |
| Low SLC8A1 in Colorectal Cancer Dictates Radiotherapy Resistance Through Calcium-Dependent ANXA2+sEVs Driving M2 Polarization of TAMs. | Adv Sci (Weinh) | 2026 | 42658530 | PubTator, text mining | PubMed |
| Warfarin-Induced Developmental Toxicity: Insights into Embryogenesis, Teratogenicity, and Molecular Pathways. | J Dev Biol | 2026 | 42647228 | PubTator, text mining | PubMed |
| AXL is associated with STAT3 activation in breast cancer. | Mol Clin Oncol | 2026 | 42614716 | PubTator, text mining | PubMed |
| Yorkie/YAP Interactors: Fine-Tuning the Hippo Pathway Output. | Cold Spring Harb Perspect Biol | 2026 | 42575696 | PubTator, text mining | PubMed |
1 to 10 of 2,064
See all 2,064 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8205
GET https://conductscience.org/api/genes/v1/8205/grants?page=2